IDP mediated transcriptional stabilization as a cause of AML

NIH RePORTER · NIH · R01 · $289,950 · view on reporter.nih.gov ↗

Abstract

PROJECT SUMMARY High expression of the intrinsically disordered protein Meningioma-1 (MN1) is common in AML, and associated with a poor prognosis. Forced expression of MN1 in murine hematopoietic progenitors induces an aggressive leukemia. We recently discovered that the primary interaction partner of MN1 is the BAF nucleosome-positioning complex. MN1 stabilizes BAF on chromatin. MN1 binding is associated with sustained active enhancer chromatin at enhancers regulating a hematopoietic stem/progenitor program. Intriguingly, MN1’s entire coding frame is disordered. We hypothesize that MN1 causes AML by overstabilizing transcriptional hubs by increasing multi- valent, low affinity interactions that result in high local concentrations of BAF and early hematopoietic transcription factors. A better understanding of how MN1 causes leukemia may identify opportunities for targeted therapies in a patient population who is failing conventional AML therapy.

Key facts

NIH application ID
10419497
Project number
1R01CA269788-01
Recipient
CHILDREN'S HOSP OF PHILADELPHIA
Principal Investigator
KATHRIN M BERNT
Activity code
R01
Funding institute
NIH
Fiscal year
2022
Award amount
$289,950
Award type
1
Project period
2022-04-01 → 2027-03-31